WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Leap Therapeutics, Inc. | February 01, 2022
Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials.
DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...
Xylyx Bio | September 30, 2020
Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to hum...
evonetix | April 04, 2022
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...
Ligand Pharmaceuticals | July 29, 2021
Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions.
The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE